Menu Search
Equities

Vivoryon Therapeutics NV

05Y:FRA

Vivoryon Therapeutics NV

Actions
  • Price (EUR)0.653
  • Today's Change0.004 / 0.62%
  • Shares traded1.62k
  • 1 Year change-95.25%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.

  • Revenue in EUR (TTM)-3.62m
  • Net income in EUR-28.34m
  • Incorporated--
  • Employees15.00
  • Location
    Vivoryon Therapeutics NVWeinbergweg 22HALLE 06120GermanyDEU
  • Phone+49 3 455559900
  • Fax+49 3 455559901
  • Websitehttps://www.vivoryon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.